William B. Jones, Ph.D., serves as Senior Vice President of Pharmaceutical Development at Corvus Pharmaceuticals Inc., where he oversees the chemistry, manufacturing, and controls (CMC) activities for the company's innovative immunotherapy portfolio targeting cancer and infectious diseases. With more than 25 years of experience in biopharmaceutical development, Dr. Jones brings deep expertise in advancing small molecules and biologics from discovery through clinical stages and commercial readiness. He earned his Ph.D. in Pharmaceutical Sciences from the University of California, San Francisco, and completed postdoctoral training at the National Cancer Institute. Prior to joining Corvus in 2020, Dr. Jones held progressive leadership roles at leading biotech and pharmaceutical companies, including Vice President of CMC at Gilead Sciences, where he led the development and regulatory approval of multiple antiviral therapies, and Director of Pharmaceutical Development at Array BioPharma (acquired by Pfizer), contributing to oncology candidates that progressed to late-stage trials. His achievements include spearheading over 15 Investigational New Drug (IND) applications, optimizing formulations for enhanced bioavailability, and implementing scalable manufacturing processes that reduced costs by up to 30% while ensuring GMP compliance. At Corvus, Dr. Jones drives the CMC strategy for key pipeline assets such as soquelitinib (CPI-818), a selective ITK inhibitor, and other covalent small molecules, positioning the company for efficient clinical advancement and potential partnerships. A prolific innovator, he holds 12 patents, has authored over 40 peer-reviewed publications, and is a frequent speaker at industry conferences on drug delivery and process chemistry.